Cardiac allograft vasculopathy (CAV) remains the Achilles' heel of long-term survival after
heart transplantation. Almost one-third of patients develop CAV by 5 years post-transplant …

Cardiac allograft vasculopathy (CAV) continues to limit the long-term success of cardiac
transplantation. Recent insights have underscored the fact that innate and adaptive immune …

The development of cardiac allograft vasculopathy remains the Achilles heel of cardiac
transplantation. Unfortunately, the definitions of cardiac allograft vasculopathy are diverse …

Background Everolimus, a novel proliferation inhibitor and immunosuppressive agent, may
suppress cardiac-allograft vasculopathy. We conducted a randomized, double-blind, clinical …

Preformed donor HLA-specific antibodies are a known indicator for poor patient survival
after cardiac transplantation. The role of de novo donor-specific antibodies (DSA) formed …

Nitric oxide (NO) is an intra-and inter-signaling molecule that regulates vessel dilatation,
neuronal transmission, cardiac contraction, immunomodulation, and stem cell differentiation …

Background—Cardiac transplantation vasculopathy is the leading cause of late death in
heart transplantation recipients. Rapamycin is an immunosuppressant drug with potent …

Despite advances in pharmacologic and device treatment of chronic heart failure, long-term
morbidity and mortality remain high, and many patients progress to end-stage heart failure …

Cardiac allograft vasculopathy (CAV) is a major factor limiting long-term survival after
cardiac transplantation. CAV is an accelerated form of coronary artery disease (CAD) that is …

Cardiovascular disease post-transplant, particularly ischemic heart disease, is a significant
problem for all transplant recipients. The major risk factors—smoking, obesity, diabetes …